Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.
1. A method for treatment of disorders involving leaky or damaged tight junctions and weak, diseased, or injured extracellular matrix comprising
administering to a human in need thereof a formulation comprising self-assembling peptides, wherein the self-assembling peptides consist of a sequence of from 8 to 16 amino acid residues conforming to one or more of Formulas I-IV:
((Xaa neu −Xaa + ) x (Xaa neu −Xaa − ) y ) n (I)
((Xaa neu −Xaa − ) x (Xaa neu −Xaa + ) y ) n (II)
((Xaa + −Xaa neu ) x (Xaa − −Xaa neu ) y ) n (III)
((Xaa − −Xaa neu ) x ((Xaa + −Xaa neu ) y ) n (IV)
wherein Xaa neu represents alanine; Xaa + represents arginine or lysine; Xaa − represents aspartic acid or glutamic acid; x and y are integers having a value of 1 or 2, or 3, or 4, independently; and n is an integer having a value of 14,
wherein the formulation has a total concentration of less than 5 mM Li+, Na+, K+, and Cs+ ions and a concentration of self-assembling peptides between 1.0% weight to volume and 4.0% weight to volume, inclusive,
wherein the formulation is administered into a site selected from the group consisting of the blood stream and the interior of the intestines, and
wherein the self-assembling peptides assemble within the paracellular spaces between cells having leaky or damaged tight junctions and weak, diseased, or injured extracellular matrix,
and wherein the amount and concentration of self-assembling peptides is effective to form a barrier structure to prevent or limit the movement of blood and bodily fluids through leaky or damaged tight junctions and weak, diseased, or injured extracellular matrix.
2. The method of claim 1 , wherein the formulation further comprises a pharmaceutically acceptable carrier for administration in the body.
3. The method of claim 2 , wherein the formulation comprises a dry powder, a wafer, a disk, a tablet, a capsule, a liquid, a gel, nano or microparticles, a polymeric matrix, or a polymeric or fibrous structure.
4. The method of claim 1 , wherein x and y are 1 and n is 4.
5. The method of claim 1 , wherein the self-assembling peptides comprise a sequence of amino acid residues conforming to Formula III or Formula IV.
6. The method of claim 1 , wherein the self-assembling peptides comprise the amino acid sequence RADARADARADARADA (SEQ ID NO: 60).
7. The method of claim 1 , wherein the amino acid residues are naturally occurring amino acid residues.
8. The method of claim 7 , wherein the naturally occurring amino acid residues are suitable for cell growth and repair.
9. The method of claim 1 for the treatment and support of intestinal walls.
10. The method of claim 1 for the treatment and support of tubular structures such as urethra, intestine, veins, arteries, bile ducts.
11. The method of claim 1 for the treatment of necrotic tissue or damaged tissue in stomach.
12. The method of claim 1 , wherein the peptide is administered into the blood stream.
13. The method of claim 1 , wherein the composition is administered in an amount sufficient to provide a reservoir of self-assembling peptides within the body to provide self-assembling material as needed throughout the flowing system.
14. The method of claim 9 , wherein the formulation is injected or otherwise introduced into the interior of an organ.